ADB-BUTINACA acts as an agonist at CB1 and CB2 receptors, mimicking the results of pure cannabinoids. It is usually Utilized in investigation to review receptor interactions and their impact on the central nervous method. ADB – Butinaca is a controlled substance added to Schedule II in 2023